January 15, 2026 – Cardinal Well being supplied an replace to its fiscal yr 2026 monetary steerage and plans to focus on vital progress on its strategic progress initiatives through the 44^e Annual JP Morgan Healthcare Convention.

Bettering the 2026 finances outlook

Cardinal Well being is elevating its fiscal 2026 non-GAAP diluted earnings per share steerage to no less than $10.00, up from its earlier steerage vary of $9.65 to $9.85. This improved outlook is pushed by robust efficiency and execution throughout the corporate’s 5 working segments. The corporate will present additional particulars and updates on its upcoming second quarter earnings outcomes on February 5, 2026.

Accelerating the expansion of specializations

Cardinal Well being now expects greater than $50 billion in income from Specialty companies in fiscal 2026, representing a 16% CAGR over three years². This progress is pushed by sturdy demand in specialty distribution, the growth of the corporate’s MSO platforms and anticipated income progress of greater than 30% at BioPharma Options in fiscal 2026.

In BioPharma Options, Cardinal Well being highlights the successes of its Sonexus™ Entry and Affected person Assist actions. A number of main producer companions lately chosen Sonexus™ for his or her affected person help hub applications, which collectively serve greater than 1 million sufferers. This contains the transition to Sonexus™ of Sanofi and Regeneron’s Dupixent My Approach affected person help program, acknowledged as one of many largest within the {industry}, and a number of other oncology applications from main producers.

These successes are the results of Cardinal Well being’s deliberate investments in product innovation and know-how, together with the next-generation hub that digitizes and automates the affected person help journey.

Efficiently Navigate IRA Adjustments

The Firm has efficiently transformed its distribution agreements with producers for all branded pharmaceutical merchandise affected by the 2026 Medicare Drug Worth Negotiation Program modifications previous to January 1, 2026.^st date of implementation.

Reflective of its industry-leading worth proposition, Cardinal Well being expects to proceed to be appropriately compensated for its crucial function in healthcare, delivering pharmaceutical merchandise safely, securely and effectively to finish clients nationwide.

Introducing ContinuCare™ Pathway

In an effort to leverage its full portfolio to help all of its clients, additional simplify administration of diabetes choices and enhance affected person entry, Cardinal Well being’s at-Residence Options enterprise pronounces the revolutionary ContinuCare™ Pathway program, powered by the continued integration of its acquisition of Superior Diabetes Provide.

ContinuCare™ Pathway helps pharmacies and sufferers navigate advanced insurance coverage necessities by offering a singular pharmacy-to-provider referral pathway for direct house supply to the affected person of lined diabetes provides, resembling steady glucose displays.

Publix Tremendous Markets Inc., a number one grocery chain and up to date new buyer of Cardinal Well being Pharmaceutical and Specialty Options, has now enrolled its complete pharmacy community of almost 1,400 pharmacies into this system, bringing the ContinuCare™ Pathway program to greater than 11,000 retail and grocery pharmacies.

Webcast investor occasions

The corporate will current on the JP Morgan Healthcare Convention on January 13, starting at midday Jap.

To entry the webcasts and related shows, go to Cardinal Well being’s Investor Relations web page. No entry code is required. Presentation slides and a replay of the webcast will likely be obtainable on the Investor Relations web page for 12 months.

Learn extra from Cardinal Well being.